| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by financing activities | 9,893 | 9,740 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | -29 | -25 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -30,413 | -20,644 |
| Cash and cash equivalents at beginning of period | 168,729 | - |
| Cash and cash equivalents at end of period | 138,316 | - |
Alto Neuroscience, Inc. (ANRO)
Alto Neuroscience, Inc. (ANRO)